miRagen Therapeutics Expands Executive Leadership Team Adding Drug Development Veteran

  miRagen Therapeutics Expands Executive Leadership Team Adding Drug
  Development Veteran

Dr. David Rodman Joins as Executive Vice President of Research and Development

Business Wire

BOULDER, Colo. -- March 25, 2014

miRagen Therapeutics, Inc., a biopharmaceutical company discovering and
developing innovative microRNA (miRNA)-targeting therapeutics, today announced
the appointment of David Rodman, M.D. to the position of Executive Vice
President of Research and Development. Dr. Rodman is an accomplished industry
veteran who brings significant translational medicine and clinical development
experience to the company’s executive leadership team.

“Dr. Rodman is a recognized leader in innovative drug development approaches.
His addition to our executive management team coincides with an important
period at miRagen as we plan for the advancement of programs from discovery
research into clinical development,” said William S. Marshall, Ph.D.,
President and Chief Executive Officer. “We believe miRagen is well positioned
to capitalize on our cutting edge research as we continue to transition
promising projects into clinical evaluation. I’m very pleased that Dr. Rodman
will be helping to bring important medicines to patients in need.”

Dr. Rodman has more than 25 years of experience in “bench to bedside”
research. He is an elected member of the American Society for Clinical
Investigation, was named a Fellow and Established Investigator of the American
Heart Association, and was a founding member of the Cystic Fibrosis
Therapeutics Development Network. Prior to joining miRagen, Dr. Rodman was a
Vice President of Clinical Development at Vertex Pharmaceuticals Incorporated,
and before that he was Executive Director, Respiratory Translational Medicine
at the Novartis Institutes for Biomedical Research. Dr. Rodman, who was a
tenured Professor of Medicine at the University of Colorado, holds a medical
degree from the University of Pennsylvania and has authored more than 100
publications.

Dr. Rodman has led cross-functional teams across the R&D spectrum from basic
cell and molecular biology, through first-in-human proof-of-concept trials, to
successful pivotal trials. The teams he has led have delivered multiple
successful IND and CTA applications in the US, Europe and developing
countries. While at Vertex, teams he led participated in the development of
Vertex’s portfolio of approved and investigational cystic fibrosis medicines,
which have all received Breakthrough Therapy Designation from the U.S. FDA.

“With a pipeline of innovative micro-RNA programs and a focus on diseases with
high unmet medical need, I believe miRagen is well positioned to successfully
translate microRNA biology into RNA-based therapies for individuals suffering
from rare and neglected diseases,” said Dr. Rodman. “I am excited to join this
talented team and be part of the next stage in the development of miRagen
Therapeutics.”

About microRNAs

MicroRNAs have emerged as an important class of small RNAs encoded in the
genome, acting as master regulators of gene expression. Recent studies have
indicated that microRNAs appear to be associated with many disease processes.
Because they are thought to be single molecular entities that dictate the
expression of fundamental regulatory pathways, microRNAs represent potential
drug targets for controlling many biologic and disease processes.^1

About miRagen Therapeutics, Inc.

miRagen Therapeutics, Inc., is a biopharmaceutical company focused on the
discovery and development of innovative microRNA (miRNA)-targeting therapies,
specifically in disease areas of high unmet medical need. The company seeks to
leverage in-house expertise in miRNA biology, oligonucleotide chemistry, and
drug development to evaluate and advance promising technologies and
high-potential drug candidates for its own pipeline and in conjunction with
strategic partners. For certain cardiovascular disease programs, miRagen has
partnered with Servier, a leading private European pharmaceutical company.
miRagen retains all rights for the Servier-partnered programs in the United
States and Japan. With its commercial and academic alliances, miRagen seeks to
harness the power of microRNA biology by translating discoveries into
breakthrough therapies that have the potential to improve human health. For
more information, please visit www.miragenrx.com.

  1)   Mendell, J.T. and Olson, E.N. (2012). MicroRNAs in Stress Signaling
           and Human Disease. Cell 148, 1172-1187.

Contact:

miRagen:
Kecia Carroll, 720-933-0848
Communications
Kecia@kcroberg.com
 
Press spacebar to pause and continue. Press esc to stop.